Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd - R) In High Risk Smoldering Multiple Myeloma Patients

被引：3
|
作者：
Landgren, Ola
Mailankody, Sham
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Zingone, Adriana
Costello, Rene
Burton, Debra
Zhang, Yong
Wu, Peter
Carter, George
Mulquin, Marcia
Zuchlinski, Diamond
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Roschewski, Mark
Korde, Neha
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1939.1939
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1939
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE II CLINICAL AND CORRELATIVE STUDY OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE EXTENDED DOSING (CRD-R) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
    Korde, N.
    Zingone, A.
    Kwok, M.
    Manasanch, E.
    Wu, P.
    Tageja, N.
    Bhutani, M.
    Flanders, A.
    Costello, R.
    Mulquin, M.
    Zuchlinski, D.
    Roschewski, M.
    Maric, I.
    Calvo, K.
    Braylan, R.
    Yuan, C.
    Stetler-Stevenson, M.
    Arthur, D.
    Xi, L.
    Raffeld, M.
    Lindenberg, M.
    Choyke, P.
    Kurdziel, K.
    Steinberg, S.
    Lee, M.
    Trepei, J.
    Landgren, O.
    HAEMATOLOGICA, 2013, 98 : 98 - 99
  • [2] Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary L.
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Mailankody, Sham
    Costello, Rene
    Zhang, Yong
    Burton, Debra
    Carter, George
    Wu, Peter
    Mulquin, Marcia
    Zuchlinski, Diamond
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Roschewski, Mark
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Pete
    Steinberg, Seth M.
    Landgren, Ola
    BLOOD, 2013, 122 (21)
  • [3] Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
    Kazandjian, Dickran
    Hill, Elizabeth
    Morrison, Candis
    Dew, Alexander
    Korde, Neha
    Mailankody, Sham
    Manasanch, Elisabet E.
    Kwok, Mary L.
    Bhutani, Manisha
    Tageja, Nishant
    Zhang, Yong
    Carpenter, Ashley
    Epstein, Monica
    Emanuel, Michael
    Lu, Crystal
    Braylan, Raul C.
    Calvo, Katherine R.
    Choyke, Peter
    Dulau-Florea, Alina
    Mena, Esther
    Lindenberg, Liza
    Maric, Irina
    Patel, Nisha
    Stetler-Stevenson, Maryalice
    Wang, Hao-Wei
    Yuan, Constance M.
    Steinberg, Seth M.
    Figg, William D.
    Roschewski, Mark
    Landgren, Ola
    BLOOD, 2020, 136
  • [4] Pretreatment Plasma Cell Proteasome Levels Predict Responses To Treatment With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed By Lenalidomide Extended Dosing (CRd-R) In Newly Diagnosed Multiple Myeloma Patients
    Maric, Irma
    Simakova, Olga
    Korde, Neha
    Zingone, Adriana
    Costello, Rene
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Carter, George
    Mulquin, Marcia
    Zuchlinski, Diamond
    Roschewski, Mark
    Landgren, Ola
    BLOOD, 2013, 122 (21)
  • [5] Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Costello, Rene
    Zuchlinski, Diamond
    Mulquin, Marcia
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Tembhare, Prashant Ramesh
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Raffeld, Mark
    Xi, Liqiang
    Choyke, Peter
    Kurdziel, Karen
    Lindenberg, Liza
    Steinberg, Seth M.
    Roschewski, Mark
    Landgren, Ola
    BLOOD, 2012, 120 (21)
  • [6] Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Costello, Rene
    Yancey, Mary Ann
    Mulquin, Marcia
    Calvo, Katherine R.
    Maric, Irina
    Tembhare, Prashant
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane Carol
    Choyke, Peter L.
    Kurdziel, Karen A.
    Steinberg, Seth M.
    Raffeld, Mark
    Roschewski, Mark J.
    Landgren, Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma A Phase 2 Nonrandomized Controlled Trial
    Kazandjian, Dickran
    Hill, Elizabeth
    Dew, Alexander
    Morrison, Candis
    Roswarski, Joseph
    Korde, Neha
    Emanuel, Michael
    Petrosyan, Ani
    Bhutani, Manisha
    Calvo, Katherine R.
    Dulau-Florea, Alina
    Kwok, Mary
    Lee, Min-Jung
    Lee, Sunmin
    Lindenberg, Liza
    Mailankody, Sham
    Manasanch, Elisabet
    Maric, Irina
    Mena, Esther
    Patel, Nisha
    Tageja, Nishant
    Trepel, Jane B.
    Turkbey, Baris
    Wang, Hao-Wei
    Wang, Weixin
    Yuan, Constance
    Zhang, Yong
    Braylan, Raul
    Choyke, Peter
    Stetler-Stevenson, Maryalice
    Steinberg, Seth M.
    Figg, William D., Sr.
    Roschewski, Mark
    Landgren, Ola
    JAMA ONCOLOGY, 2021, 7 (11) : 1678 - 1685
  • [8] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
    Korde, Neha
    Roschewski, Mark
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Mailankody, Sham
    Wu, Peter
    Morrison, Candis
    Costello, Rene
    Zhang, Yong
    Burton, Debra
    Mulquin, Marcia
    Zuchlinski, Diamond
    Lamping, Liz
    Carpenter, Ashley
    Wall, Yvonne
    Carter, George
    Cunningham, Schuyler C.
    Gounden, Verena
    Sissung, Tristan M.
    Peer, Cody
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Kong, Katherine A.
    Weng, Li
    Faham, Malek
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Peter
    Steinberg, Seth M.
    Figg, William
    Landgren, Ola
    JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
  • [9] A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
    Bhutani, Manisha
    Foureau, David M.
    Robinson, Myra
    Guo, Fei
    Fesenkova, Kateryna
    Atrash, Shebli
    Paul, Barry
    Varga, Cindy
    Friend, Reed
    Pineda-Roman, Mauricio
    Rigby, Katherine
    Symanowski, James T.
    Norek, Sarah
    Tucker, Mallory R.
    Druhan, Lawrence J.
    Voorhees, Peter M.
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 535 - +
  • [10] Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study
    Mailankody, Sham
    Salcedo, Meghan
    Tavitian, Elizabet
    Burge, Miranda
    Korde, Neha
    Hassoun, Hani
    Lesokhin, Alexander
    Lahoud, Oscar
    Smith, Eric
    Hultcrantz, Malin
    Tan, Carlyn
    Shah, Urvi
    Devlin, Sean
    Landgren, Ola
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2760 - 2761
12345